替格瑞洛与氯吡格雷早期治疗CYP2C19功能缺失携带者卒中或TIA试验的一年结局
CHANCE-2试验1年随访显示,在CYP2C19功能缺失等位基因携带的轻型缺血性卒中或TIA患者中,替格瑞洛联合阿司匹林组1年新发卒中风险低于氯吡格雷联合阿司匹林组(7.91% vs 9.73%,HR 0.80,95%CI 0.68-0.95,p=0.007),严重或中度出血无显著差异。
要点
- CYP2C19功能缺失携带者轻型卒中/TIA后,替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低1年新发卒中风险。
- 3个月至1年期间新发卒中两组无显著差异(2.07% vs 2.32%,p=0.48)。
- 严重或中度出血两组无显著差异(0.53% vs 0.63%,p=0.61)。
核心结论
- 对于CYP2C19功能缺失等位基因携带者,早期替格瑞洛双联抗血小板治疗在1年时降低复发性卒中优于氯吡格雷。
研究设计与样本
- CHANCE-2试验为在中国202个中心进行的随机、双盲、安慰剂对照试验。
- 共纳入6412例CYP2C19功能缺失等位基因携带的轻型卒中或TIA患者,症状发作24小时内按1:1随机分组。
- 替格瑞洛-阿司匹林组接受替格瑞洛加氯吡格雷安慰剂,氯吡格雷-阿司匹林组接受氯吡格雷加替格瑞洛安慰剂,疗程90天;两组前21天均接受阿司匹林。
- 90天后治疗由临床医生和患者选择。
主要发现
- 1年随访时,替格瑞洛-阿司匹林组新发卒中252例(7.91%),氯吡格雷-阿司匹林组310例(9.73%)(HR 0.80;95%CI 0.68-0.95;p=0.007)。
- 3个月至1年期间新发卒中:替格瑞洛-阿司匹林组61例(2.07%) vs 氯吡格雷-阿司匹林组67例(2.32%)(p=0.48)。
- 严重或中度出血:替格瑞洛-阿司匹林组17例(0.53%) vs 氯吡格雷-阿司匹林组20例(0.63%)(p=0.61)。
- 3个月至1年期间抗血小板用药分布:替格瑞洛-阿司匹林组替格瑞洛加阿司匹林0.09%、氯吡格雷加阿司匹林1.56%、替格瑞洛单药0.13%、氯吡格雷单药2.66%、阿司匹林单药73.65%、其他抗血小板0.78%、无抗血小板21.13%;氯吡格雷-阿司匹林组分别为0.03%、1.63%、0.19%、2.60%、72.83%、0.66%、22.06%。
关键数值与推荐
- 该研究提供Class II证据:对于携带CYP2C19功能缺失的轻型卒中或TIA患者,替格瑞洛联合阿司匹林21天在降低1年复发性卒中风险方面优于氯吡格雷联合阿司匹林。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that among Chinese patients with minor ischemic stroke or transient ischemic attack (TIA) who were carriers of CYP2C19 loss-of-function alleles, dual-antiplatelet therapy with ticagrelor-aspirin reduced the 90-day risk of stroke without increased severe or moderate bleeding compared with clopidogrel-aspirin. However, whether dual-antiplatelet therapy with ticagrelor was superior to clopidogrel beyond the 90 days of follow-up remained unclear. In this study, we reported 1-year follow-up outcomes of the CHANCE-2 trial. METHODS: The CHANCE-2 trial is a randomized, double-blind, placebo-controlled trial at 202 centers in China. Patients with a minor stroke or TIA who carried CYP2C19 loss-of-function alleles were randomized within 24 hours after symptom onset, in a 1:1 ratio, to receive ticagrelor and placebo clopidogrel or to receive clopidogrel and placebo ticagrelor for 90 days; both groups received aspirin for the first 21 days. After day 90, treatment was as per the choice of the clinician and the patient. RESULTS: Among 6,412 patients, the proportion of patients on ticagrelor plus aspirin, clopidogrel plus aspirin, ticagrelor alone, clopidogrel alone, aspirin alone, other antiplatelet, and no antiplatelet beyond month 3 to 1 year was 0.09%, 1.56%, 0.13%, 2.66%, 73.65%, 0.78%, and 21.13% in the ticagrelor-aspirin group and 0.03%, 1.63%, 0.19%, 2.60%, 72.83%, 0.66%, and 22.06% in the clopidogrel-aspirin group, respectively. The primary outcome of new stroke occurred in 252 patients (7.91%) in the ticagrelor-aspirin group and 310 patients (9.73%) in the clopidogrel-aspirin group by 1 year of follow-up (hazard ratio 0.80; 95% CI 0.68-0.95; p = 0.007); new stroke beyond 3 months to 1 year occurred in 61 patients (2.07%) and 67 patients (2.32%) (p = 0.48), respectively. Primary safety outcome of severe or moderate bleeding occurred in 17 patients (0.53%) in the ticagrelor-aspirin group and 20 patients (0.63%) in the clopidogrel-aspirin group (p = 0.61). DISCUSSION: For CYP2C19 loss-of-function allele carriers, early dual-antiplatelet therapy with ticagrelor is superior to clopidogrel at 1 year in reducing recurrent stroke. TRIAL REGISTRATION INFORMATION: URL: clinicaltrials.gov. Unique identifier: NCT04078737. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with minor stroke or TIA with TIACYP2C19 loss-of-function, ticagrelor plus aspirin for 21 days is superior to clopidogrel plus aspirin in reducing the 1-year risk of recurrent stroke.
引用
- Meng X, Wang A, Tian X, et al. One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial. Neurology. 2024. PMID: 38181311. doi:10.1212/WNL.0000000000207809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。